Citations

Clear

6273 citation(s) found for "To, Andrew".

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) Alternating with Pralatrexate (P) as front line therapy for patients
Advani, Ranjana H. , Ansell, Stephen M. , Lechowicz, Mary Jo , Beaven, Anne , Loberiza, Fausto R., Carson, Kenneth R. , Evens, Andrew M. , Pro, Barbara, Pinter‐Brown, Lauren , Smith, Sonali M. , Shustov, Andrei R., Foss, Francine M. , Horwitz, Steven M. , Savage, Kerry J. , Vose, Julie M. , Advani, Ranjana H , Evens, Andrew M

Mayo Clinic

British Journal of Haematology | December 2, 2015 | Volume: 172 | Issue: 4 | Pages: 535-544

10.1111/bjh.13855 | PMID 26627450 Get It

Summary Peripheral T‐cell lymphomas ( PTCL ) have suboptimal outcomes using conventional CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. The anti‐folate pralatrexate, the first drug approved for patients with relapsed/refractory PTCL , provided a rationale to incorporate it into the front‐line setting. This phase 2 study evaluated a novel front‐line combination whereby cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) alternated with pralatrexate ( CEOP ‐P) in PTCL . Patients achieving a complete or partial remission ( CR / PR ) were eligible for consolidative stem cell transplantation ( SCT ) after 4 cycles. Thirty‐three stage II ‐ IV PTCL patients were treated: 21 PTCL ‐not otherwise specified (64%), 8 angioimmunoblastic T cell lymphoma (24%) and 4 anaplastic large cell lymphoma (12%). The majority (61%) had stage IV disease and 46% were International Prognostic Index high/intermediate or high risk. Grade 3–4 toxicities included anaemia (27%), thrombocytopenia (12%), febrile neutropenia (18%), mucositis (18%), sepsis (15%), increased creatinine (12%) and liver transaminases (12%). Seventeen patients (52%) achieved a CR . The 2‐year progression‐free survival and overall survial, were 39% (95% confidence interval 21–57) and 60% (95% confidence interval 39–76), respectively. Fifteen patients (45%) (12 CR ) received SCT and all remained in CR at a median follow‐up of 21·5 months. CEOP ‐P did not improve outcomes compared to historical data using CHOP . Defining optimal front line therapy in PTCL continues to be a challenge and an unmet need.
The Sphenopalatine Ganglion: Anatomy, Pathophysiology, and Therapeutic Targeting in Headache
Robertson, Carrie E. , Kaplan, Eugene D. , Kuruvilla, Deena E. , Blumenfeld, Andrew , Berliner, Randall, Rosen, Noah , Duarte, Robert , Vidwan, Jaskiran, Halker, Rashmi, Gill, Nicole, Halker, Rashmi B, Robbins, Matthew S. , Ailani, Jessica , Charleston, Larry , Ashkenazi, Avi , Robertson, Carrie E

Mayo Clinic

Headache: The Journal of Head and Face Pain | November 30, 2015 | Volume: 56 | Issue: 2 | Pages: 240-258

10.1111/head.12729 | PMID 26615983 Get It

The sphenopalatine ganglion (SPG) has attracted the interest of practitioners treating head and face pain for over a century because of its anatomical connections and role in the trigemino‐autonomic reflex. In this review, we discuss the anatomy of the SPG, as well as what is known about its role in the pathophysiology of headache disorders, including cluster headache and migraine. We then address various therapies that target the SPG, including intranasal medication delivery, new SPG blocking catheter devices, neurostimulation, chemical neurolysis, and ablation procedures.
Co‐registration of angiography and intravascular ultrasound images through image‐based device tracking
Prasad, Megha , Cassar, Andrew, Fetterly, Kenneth A. , Bell, Malcolm R. , Theessen, Heike, Ecabert, Olivier, Bresnahan, John F., Bell, Malcolm, Lerman, Amir

Mayo Clinic

Catheterization and Cardiovascular Interventions | November 28, 2015 | Volume: 88 | Issue: 7 | Pages: 1077-1082

10.1002/ccd.26340 | PMID 26614387 Get It

ObjectivesTo determine the feasibility of automated co‐registration of angiography and intravascular ultrasound (IVUS) to facilitate integration of these two imaging modalities in a synchronous manner.BackgroundIVUS provides cross‐sectional imaging of coronary arteries but lacks overview of the vascular territory provided by angiography. Co‐registration of angiography and IVUS would increase utility of IVUS in the clinical setting.MethodsForty‐nine consecutive patients undergoing surveillance for cardiac allograft vasculopathy with angiography and IVUS of the left anterior descending artery (LAD) were enrolled. A pre‐IVUS angiogram of the LAD was performed followed by an ECG‐triggered fluoroscopy (ECGTF) during IVUS pullback at 0.5 mm/s using an automatic pullback device. ECGTF was used to track the IVUS catheter during pullback and establish a spatial relationship to the pre‐IVUS angiogram. Angio‐IVUS co‐registration was performed with a research prototype (Siemens Healthcare, Germany) and accuracy was evaluated by distance mismatch between angiography and IVUS images at vessel bifurcations.ResultsMedian age was 54 (44.5, 67) years. The population was 82.6% male with minimal risk factors. The median (IQR) co‐registration distance mismatch measured at 108 bifurcations in 42 (85%) patients was 0.35 (0.00–1.16) mm. Seven patients were excluded due to inappropriate data acquisition (n = 3) and failure of tracking (n = 4), e.g., due to overlapping sternal wires. Estimated effective radiation dose for ECGTF was 0.09 mSv.ConclusionThis study demonstrates the feasibility of angio‐IVUS co‐registration which may be used as a clinical tool for localizing IVUS cross‐sections along an angiographic roadmap. © 2015 Wiley Periodicals, Inc.
Application of Epstein‐Barr Virus Serology to the Diagnosis and Staging of North American Patients with Nasopharyngeal Carcinoma
Neel, H. Bryan, Pearson, Gary R., Weiland, Louis H., Taylor, William F., Goepfert, H, Pilch, Ben Z., Lanier, Anne P., Huang, Andrew T. , Hyams, Vincent J., Levine, Paul H., Henle, Gertrude, Henle, Werner, Goodman, Max Justin

Mayo Clinic

Otolaryngology–Head and Neck Surgery | November 25, 2015 | Volume: 91 | Issue: 3 | Pages: 255-262

10.1177/019459988309100310 | PMID 6308537 Get It

From 1978 to 1981, 151 patients with nasopharyngeal carcinoma (NPC) were enrolled in a prospective, collaborative study of North American patients, most of them white. Thirty‐seven had World Health Organization (WHO) type 1 tumors, and 114 had WHO types 2 and 3 tumors. The anti‐Epstein‐Barr virus (EBV) profile of elevated antibody titers directed against viral capsid antigen and early antigen was seen in 85% of the patients with WHO types 2 and 3 tumors but in only 16% of the patients with WHO type 1 tumors. Geometric mean titers tended to be higher in higher stages of the disease in several staging systems. Low antibody‐dependent cellular cytotoxicity at diagnosis appears to reflect a poorer prognosis, and the determination of antibody titers by this assay may prove to be useful for identifying persons in whom recurrent disease is likely to develop after conventional therapy. Anti‐EBV titers can aid in diagnosis and treatment planning in patients with NPC, particularly those with occult primary NPC.
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Piccart, Martine , Holmes, Eileen , Baselga, José , Azambuja, Evandro de , Dueck, Amylou C. , Viale, Giuseppe , Zujewski, Jo Anne , Goldhirsch, Aron, Armour, Alison, McCullough, Ann E. , Dolci, Stella, McFadden, Eleanor, Holmes, Andrew , Tonghua, Liu, Eidtmann, Holger, Dinh, Phuong , Cosimo, Serena Di , Tjulandin, Sergei , Im, Young‐Hyuck , Huang, Chiun‐Sheng , Wolff, Antonio C. , Jackisch, Christian , Láng, István, Boyle, Frances , Gómez, Henry , Gelber, Richard D. , Perez, Edith A. , Piccart-Gebhart, Martine, de Azambuja, Evandro, Pritchard, Kathleen I. , Holmes, Andrew P, Di Cosimo, Serena, Harbeck, Nadia , Dièras, Véronique , Hillman, David W. , Untch, Michael , Smith, Ian , Xu, Binghe , Suter, Thomas, Dueck, A. C. , Zujewski, Jo Anne , Tonghua, Liu, Xu, Binghe , Suter, Thomas , Wolff, Antonio C , de Azambuja, Evandro , Huang, Chiun-Sheng

Mayo Clinic

Journal of Clinical Oncology | November 23, 2015 | Volume: 34 | Issue: 10 | Pages: 1034-1042

10.1200/jco.2015.62.1797 | PMID 26598744 Get It

Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed human epidermal growth factor 2–positive early breast cancer were randomly assigned to 1 year of adjuvant therapy with T, L, their sequence (T→L), or their combination (L+T). The primary end point was disease-free survival (DFS), with 850 events required for 80% power to detect a hazard ratio (HR) of 0.8 for L+T versus T. Results Between June 2007 and July 2011, 8,381 patients were enrolled. In 2011, due to futility to demonstrate noninferiority of L versus T, the L arm was closed, and patients free of disease were offered adjuvant T. A protocol modification required P ≤ .025 for the two remaining pairwise comparisons. At a protocol-specified analysis with a median follow-up of 4.5 years, a 16% reduction in the DFS hazard rate was observed with L+T compared with T (555 DFS events; HR, 0.84; 97.5% CI, 0.70 to 1.02; P = .048), and a 4% reduction was observed with T→L compared with T (HR, 0.96; 97.5% CI, 0.80 to 1.15; P = .61). L-treated patients experienced more diarrhea, cutaneous rash, and hepatic toxicity compared with T-treated patients. The incidence of cardiac toxicity was low in all treatment arms. Conclusion Adjuvant treatment that includes L did not significantly improve DFS compared with T alone and added toxicity. One year of adjuvant T remains standard of care.
Identification of HDAC6‐Selective Inhibitors of Low Cancer Cell Cytotoxicity
Gaisina, Irina N. , TUECKMANTEL, W., Ugolkov, Andrey , Shen, Sida , Hoffen, Jessica, Dubrovskyi, Oleksii, Mazar, Andrew P. , Schoon, Renee A., Billadeau, Daniel D. , Kozikowski, Alan P.

Mayo Clinic

ChemMedChem | November 23, 2015 | Volume: 11 | Issue: 1 | Pages: 81-92

10.1002/cmdc.201500456 | PMID 26592932 Get It

AbstractThe histone deacetylases (HDACs) occur in 11 different isoforms, and these enzymes regulate the activity of a large number of proteins involved in cancer initiation and progression. The discovery of isoform‐selective HDAC inhibitors (HDACIs) is desirable, as it is likely that such compounds would avoid some of the undesirable side effects found with the first‐generation inhibitors. A series of HDACIs previously reported by us were found to display some selectivity for HDAC6 and to induce cell‐cycle arrest and apoptosis in pancreatic cancer cells. In the present work, we show that structural modification of these isoxazole‐based inhibitors leads to high potency and selectivity for HDAC6 over HDAC1–3 and HDAC10, while unexpectedly abolishing their ability to block cell growth. Three inhibitors with lower HDAC6 selectivity inhibit the growth of cell lines BxPC3 and L3.6pl, and they only induce apoptosis in L3.6pl cells. We conclude that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required. Moreover, the highly selective HDAC6Is reported herein that are weakly cytotoxic may find use in cancer immune system reactivation.
Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations
Cheungpasitporn, Wisit , Erickson, Stephen B., Enders, Felicity , Rule, Andrew D. , Lieske, John C. , Cheungpasitporn, Wisit

Mayo Clinic

Journal of Urology | November 17, 2015 | Volume: 195 | Issue: 5 | Pages: 1476-1481

10.1016/j.juro.2015.11.027 | PMID 26598423 Get It

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS)
Investigators, The Huntington Study Group PHAROS, Biglan, Kevin , Shoulson, Ira , Kieburtz, Karl , Oakes, David , Kayson, Elise, Shinaman, M. Aileen, Zhao, Hongwei , Romer, Megan, Young, Anne B., Hersch, Steven M. , Penney, Jack, Marder, Karen, Paulsen, Jane S. , Quaid, Kimberly A., Siemers, Eric , Mallonee, William, Suter, Greg, Dubinsky, Richard , Nance, Martha , Bundlie, Scott R., Radtke, Dawn, Kostyk, Sandra K. , Baic, Corrine, Walker, Francis O. , Hunt, Victoria, Chouinard, Sylvain, Wood‐Siverio, Cathy, Corey‐Bloom, Jody , Peavy, Guerry M. , Moskowitz, Carol, Wesson, Melissa, Samii, Ali, Bird, Thomas D. , Lipe, Hillary, Blindauer, Karen, Marshall, Frederick J., Zimmerman, Carol, Goldstein, Jody, Rosas, Diana, Novák, Péter , Caviness, John N., Duffy, Amy, Wheelock, Vicki, Tempkin, Teresa, Seeberger, Lauren , Albin, Roger L. , Racette, Brad A. , Perlman, Susan , Bordelon, Yvette , Martin, W. R. Wayne , Wieler, Marguerite , Raymond, Lynn A. , Decolongon, Joji, Hunter, Christine , Hauser, Robert A. , Furtado, Sarah , Suchowersky, Oksana , Klimek, Mary Lou, Guttman, Mark, Sethna, Rustom, Feigin, Andrew, Cox, Marie, Shannon, Barbara , Percy, Alan K. , Dure, Leon , Harrison, Madaline B. , Higgins, Donald S. , Molho, Eric , Nickerson, Constance, Evans, Sharon, Hobson, Douglas, Singer, Carlos , Gálvez-Jiménez, Néstor, Shannon, Kathleen M. , Comella, Cynthia , Ross, Christopher A. , Hogarth, Penelope , Weiner, William J., Como, Peter G., Kumar, Rajeev , Cotto, Candace, Stout, Julie C. , Brocht, Alicia, Watts, Arthur, Eberly, Shirley , Weaver, Christine , Gusella, James F. , MacDonald, Marcy E., Fahn, Stanley, Shults, Clifford W., Caviness, John, Investigators, The Huntington Study Group PHAROS, Tanner, Caroline M. , Gray, Carolyn Steele , Baic, Corrine L., Caress, James B. , O’Neill, Christine J. , Factor, Stewart Alan , Greenamyre, J. Timothy , Song, David , Adler, Charles H. , Richman, David P. , Chou, Kelvin L. , Perlmutter, Joel S. , Leavitt, Blair R. , Clarke, Lorne A. , Jankovic, Joseph J. , Sanchez‐Ramos, Juan , Johnson, William , Saint‐Hilaire, Marie , Testa, Claudia M. , Rosenblatt, Adam E , Foroud, Tatiana , Myers, Richard H. , Ross, Christopher A , Hauser, Robert A

Mayo Clinic

JAMA Neurology | November 16, 2015 | Volume: 73 | Issue: 1 | Pages: 102

10.1001/jamaneurol.2015.2736 | PMID 26569098 Get It

Critical Appraisal and Review of Management Strategies for Severe Fibrosis During Penile Implant Surgery
Trost, Landon , Patil, Mukul, Kramer, Andrew

Mayo Clinic

The Journal of Sexual Medicine | November 13, 2015 | Volume: 12 | Issue: Supplement_7 | Pages: 439-447

10.1111/jsm.12985 | PMID 26565574 Get It

Abstract Introduction Penile corporal fibrosis represents a challenging clinical scenario for surgeons placing penile prostheses (PP). Because of its rarity, a small number of series with limited follow-up have reported outcomes in this cohort. Aim The aim of this study was to perform a critical appraisal of the corporal excavation technique, discuss its relevance to contemporary practice, and review alternative surgical methods and outcomes. Methods A critical review was performed of the 2006 article by Montague and Angermeier, “Corporeal excavation: new technique for penile prosthesis implantation in men with severe corporeal fibrosis.” Notable inclusions and omissions were described, with emphasis placed on methodology and outcomes. A PubMed search from 1990 to June 2015 was then performed to review and summarize the literature on managing corporal fibrosis during PP surgery. Main Outcome Measures The main outcome measures used were the major contributions and limitations of the 2006 article describing outcomes of the corporal excavation technique. Results Corporal excavation is a relevant surgical technique for managing severe corporal fibrosis. Compared with alternatives, excavation achieves successful placement of PP without need for grafting and with few complications. The article was limited by several notable omissions including relevant patient demographic and disease characteristics, patient selection, and minimal descriptions of complications and outcomes. Alternative techniques include use of specialized dilators, counter incisions, reconstruction with graft placement, minimal scar tissue excision, and endoscopic resection. Because of limited data, no specific algorithm for managing corporal fibrosis can be prescribed. Conclusions Corporal fibrosis is a challenging clinical scenario and requires surgical experience and specialized techniques to manage appropriately. Corporal excavation represents one of several viable techniques, which may be chosen based on surgeon’s preference and clinical factors.
Salvage autologous fascial sling after failed synthetic midurethral sling: Greater than 3‐year outcomes
Petrou, Steven P. , Davidiuk, Andrew, Rawal, Bhupendra, Thiel, David D. , Davidiuk, Andrew J, Arnold, Michelle, Arnold, Michelle L.

Mayo Clinic

International Journal of Urology | November 13, 2015 | Volume: 23 | Issue: 2 | Pages: 178-181

10.1111/iju.13003 | PMID 26563492 Get It

ObjectiveTo determine long‐term surgical outcomes of salvage autologous fascial sling placement after a failed synthetic midurethral sling.MethodsWomen who had undergone autologous fascial sling placement without concomitant pelvic surgery for a failed synthetic midurethral sling utilizing mesh with a minimum follow up of 36 months were identified. Charts were reviewed, and patients were contacted by telephone. Success was determined by the Patient Global Impression of Improvement. Secondary measures included the Incontinence Severity Index questionnaire, patient recommendation of the autologous fascial sling and need for further incontinence surgery.ResultsA total of 35 patients met the criteria, and 21 were successfully contacted. Of those contacted, the median age at surgery was 67 years (range 53–81 years) and at the time of the survey was 75 years (range 63–84 years) with median follow up of 74 months (range 36–127 years). Preoperatively, 12 patients (57.1%) had urethral hypermobility and 13 patients (61.9%) had mixed urinary incontinence. Eight patients (38.1%) had concomitant sling excision with five of those combined with urethrolysis at the time of the salvage operation. Patient Global Impression of Improvement success was noted in 16 patients (76.2%). A total of 11 patients (52.4%) were dry or had slight incontinence by the Incontinence Severity Index. One patient required additional anti‐incontinence surgery (4.8%). A total of 18 patients (85.7%) recommended the autologous fascial sling. No statistical impact was noted with sling excision (P = 0.62), mixed urinary incontinence (P = 0.61), age at surgery (P = 0.23), age at follow up (P = 0.15), length of follow up (P = 0.71) or first surgery type (transobturator tape vs retropubic; P = 1.00).ConclusionsAutologous fascial sling provides reasonable long‐term success as a salvage operation for failed midurethral slings.